生熟三七总皂甙对蛋白质合成的影响

按序贯法给小鼠静注TSPN和PTSPN求得LD_(50)分别为110.67±14mg/kg和105.33±58.6mg/kg。当给小鼠TSPN和PTSPN灌胃或皮下注射,在适当剂量时,都能使~3H-亮氨酸参与肝、肾和血清蛋白质合成的放射性强度明显增高。但超过适当剂量时,则无作用或呈现放射性强度降低。不同脏器对这两种总皂甙的敏感性也不完全相同。     

Totally Implantable Artificial Organ: Cardiac Prosthesis

This article reviews the current status of completely implantable cardiac prostheses, with an emphasis on those systems presently under development at The Cleveland Clinic Foundation (CCF). Such devices have been one of the final goals of artificial heart research since 1957, when Dr. Kolff initiated these studies in Cleveland. Although earlier plans aimed at using radioisotopes as the energy source, more recently, due to public opinion and sociopolitical influences, the shift has been towards exclusive use of electrically activated energy converters. These systems can be roughly broken down into two groups according to the powertrain configuration. In the first group, electric heating coils maintain liquid salts in thermal batteries at temperatures close to 500 degrees C. This thermal energy is then converted (through a Stirling cycle) to mechanical motion of the pusher plate (PP) which in turn acts on the blood. Two such systems (emphasized in this article) are under development here at CCF in joint efforts with Nimbus Corporation and the University of Washington, respectively. In the second group of ventricular assist systems, electric energy is converted directly to PP motion through rotating cams, solenoids, or electrohydraulic transmission systems. At least four American contractors are working at the preclinical stage on this group of devices. One in particular, the CCF-Nimbus system, consisting of a biolized surface blood pump, an electrohydraulic energy converter, and a compliance chamber to handle the variable volume behind the PP, is described in depth in this discussion. In terms of future prospects, it is forecasted that by 1988, the completely implantable VAS will be used clinically, and that by 1994, a specially designed total artificial heart (nontethered patient) would be ready for human use.     

全直肠系膜切除联合双吻合器在低位直肠癌手术中的应用

目的 探讨全直肠系膜切除(TME)联合双吻合器(DST)在低位直肠癌手术中的应用效果.方法 回顾性分析2004年至2006年15例直肠癌应用全直肠系膜切除联合双吻合器行低位直肠前切除的临床资料及经验.结果 本组无死亡病例.无排尿及性功能障碍.吻合口狭窄2例,经扩肛后治愈.结论 全直肠系膜切除联合双吻合器的应用可保持盆腔脏器功能,是治疗低位直肠癌的有效方法.     

爱宝疗浓缩液用于宫颈糜烂的临床疗效分析

目的观察爱宝疗浓缩液对宫颈糜烂的治疗效果。方法用爱宝疗浓缩液阴道给药,隔天用药1次,6次为一疗程,于用药后1个月、2个月、3个月3个阶段观察并分析效果。结果治疗效果因宫颈糜烂程度不同而有所差异,爱宝疗对不同程度宫颈糜烂均有效,总有效率达87.5%以上。结论爱宝疗浓缩液治疗宫颈糜烂应用简便,副作用少,疗效可靠。     

黄芩自生酶催化水解总黄酮苷的工艺研究

目的研究黄芩自生酶催化水解总黄酮苷的工艺条件。方法采用正交试验，考察了加水量、温度和时间等因素，采用HPLC法测定了药材中黄芩苷、黄芩素、汉黄芩素、千层纸素-A的含量。结果确定最优酶催化水解工艺条件为取药材，加4倍量水，于32℃酶催化水解12h，烘干后备用。结论黄芩自生酶催化水解总黄酮苷是一种环保、经济、可行的方法。     

应用脉冲振荡法（IOS）测定大学生肺功能的研究

目的：为能全面反映呼吸生理和呼吸动力学特征，提供较通气功能更多的有用信息。方法：应用脉冲振荡法（im-pulseoscillometry，IOS），测定100名健康大学生5～35Hz频率下的呼吸阻抗值后，测定常规通气肺功能，其中23名男性大学生进行IOS重复试验。结果：呼吸阻抗（Zrs）＜0．5kPa／L·s-1，响应频率（Fre）10Hz左右，除R35外，5～25Hz频率下呼吸道粘性阻力R值均小于预计值的150％，预计R值与实测值间差异无显著性（P＞0．05），预计X值与实测X值间差异显著（P＜0．01）。以频率F为自变量，R与X分别为因变量作相关分析显示，R值不随振荡频率而变化，X值随振荡频率而轻度增高。阻抗微分均值图显示阻力和电抗均无流速依赖性和容积依赖性，但Resistance图显示频谱对阻力的流速有一定影响。结论：健康大学生IOS呼吸道粘性阻力参数基本正常，IOS技术重复性良好，反映弹性阻力和惯性阻力的X变化及频谱对阻力流速的影响，而常规肺功能正常。可认为IOS较适合于大学生健康普查。比传统肺功能可以较早地发现与吸烟有关的COPD潜在病变─—轻度周边阻塞。     

Cobalt, chromium, and nickel concentrations in body fluids of patients with porous-coated knee or hip prostheses

Co, Cr, and Ni concentrations were determined by electrothermal atomic absorption spectrophotometry in serum and urine specimens collected from a group of 28 patients at intervals of from 1 day to 2.5 years after total knee or hip arthroplasty with porous-coated prostheses fabricated of Co-Cr alloy (ASTM F-75-82). Two control groups were also tested: (a) 42 healthy adults and (b) 16 orthopaedic patients after total knee or hip arthroplasty with porous-coated prostheses fabricated predominantly of Ti-Al-V alloy (ASTM F-136-84). All prostheses contained polyethylene components to avoid metal-to-metal contact. Mean Co concentrations in serum and urine were slightly increased in patients with Co-Cr knee implants at 6-120 weeks after surgery, compared with (a) preoperative values, (b) corresponding values in patients with Co-Cr hip implants, and (c) corresponding values in control patients with Ti-Al-V knee and hip prostheses. Substantially increased Co levels were observed in serum and urine of two patients at 7 weeks and 22 months postarthroplasty, associated with loosening of the prostheses; one of the patients also had elevated Cr levels in serum and urine. Although ASTM F-75-82 and F-136-84 alloys contain very little Ni (less than 1.0 and less than 0.2% Ni, respectively, by wt), mean Ni concentrations in serum and urine were greatly increased at 1-2 days after implantation of Ti-Al-V and Co-Cr prostheses, diminishing by 2 weeks. The postoperative hypernickelemia and nickeluresis may reflect contamination of the operative field with Ni-containing particles from the drills, cutting jigs, and drilling jigs, or it may represent a previously unrecognized pathophysiological response to surgery.     

Total hip arthroplasty for posttraumatic osteoarthritis following acetabularfracture: A systematic review of characteristics, outcomes, and complications

Purpose: Posttraumatic arthritis (PTA) may develop years after acetabular fracture, hindering joint function and causing significant chronic musculoskeletal pain. Given the delayed onset of PTA, few studies have assessed outcomes of delayed total hip arthroplasty (THA) in acetabular fracture patients. This study systematically reviewed the literature for outcomes of THA in patients with PTA and prior acetabular fracture. Methods: Pubmed, EMBASE, SCOPUS, and Cochrane library were searched for articles containing the keywords “acetabular”, “fracture”, “arthroplasty”, and “post traumatic arthritis” published between 1995 and August 2017. Studies with less than 10 patients, less than 2 years of follow-up, conference abstracts, and non-English language articles were excluded. Data on patient demographics, surgical characteristics, and outcomes of delayed THA, including implant survival, complications, need for revision, and functional scores, was collected from eligible studies. Results: With 1830 studies were screened and data from 10 studies with 448 patients were included in this review. The median patient age on date of THA was 51.5 years, ranging from 19 to 90 years. The median time from fracture to THA was 37 months, with a range of 27-74 months. Mean follow-up times ranged from 4 to 20 years. The mean Harris hip scores (HHS) improved from 41.5 pre-operatively, to 87.6 post-operatively. The most prevalent postoperative complications were heterotopic ossification (28%-63%), implant loosening (1%-24%), and infection (0%-16%). The minimum 5-year survival of implants ranged from 70% to 100%. Revision rates ranged from 2% to 32%. Conclusion: Despite the difficulties associated with performing THA in patients with PTA from previous acetabular fracture (including soft tissue scarring, existing hardware, and acetabular bone loss) and the relatively high complication rates, THA in patients with PTA following prior acetabular fracture leads to significant improvement in pain and function at 10-year follow-up. Further high quality randomized controlled studies are needed to confirm the outcomes after delayed THA in these patients.